• TriSalus Life Sciences scheduled a June 24, 2026 virtual KOL event to discuss newly published real-world evidence for its liver cancer delivery approach.
• The study reported improved targeting of therapies to liver tumors, supporting a more consistent treatment effect versus conventional embolization.
• Findings also indicated fewer complications tied to unintended treatment outside the tumor, strengthening the technology’s risk-benefit profile.
• The discussion will cover patient selection and treatment strategy, with a focus on clinical experience using the TriNav Infusion System.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260610679269) on June 10, 2026, and is solely responsible for the information contained therein.